Could PD-(L)1/VEGF Agents Face Off First In China Phase III Trials?
As Akeso’s ivonescimab emerges as a novel standard of care for certain non-small cell lung cancers in China, it might find itself going head-to-head with other anti-PD-(L)1/VEGF bispecifics emerging in the country.
Scrip - April 21, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Icotyde could be J&J’s biggest ever product; daraxonrasib data boost Revolution; Travere’s Filspari becomes first drug for FSGS; GSK bets big on B7-H4 antibody-drug conjugate; and Lilly grabs top spot in global pharma sales.
Scrip - April 21, 2026

Medical Device Repair Controversy Back in Play
A recent survey indicates that hospital technicians, particularly those in rural hospitals, have difficulty maintaining a variety of medical devices and device capital equipment. Manufacturers are at times reluctant to provide data and keys for third-party servicers.
Medtech Insight - April 20, 2026

Medtronic Adds FFRangio To Cardiovascular Arsenal In $585M CathWorks Acquisition
Wire-based FFR has always been underused despite a strong evidence base. Medtronic's $585m CathWorks acquisition is a direct bet that AI-derived physiology from routine angiograms — no wires, no drugs — can finally make coronary physiology a standard part of every cath lab case.
Medtech Insight - April 20, 2026

FDA Proposes To Forego Premarket Review For Certain CDC-Approved Respirators
The US FDA wants to rely on oversight from the CDC’s National Institute for Occupational Safety and Health and its own post-market data for regulating certain types of respirators. The FDA says NIOSH already provides sufficient quality assurance.
Medtech Insight - April 20, 2026

Harbinger Raises $100M, Presents New Data For Cancer Tests At AACR
Harbinger Health showed off more positive data for its multi-cancer test platform at AACR after announcing $100M funding to help commercialize its first product.
Medtech Insight - April 20, 2026

Medtronic, Pulnovo Join Forces On Pulmonary Denervation After $100M Financing
Medtronic has led a $100m financing round for the Chinese cardiopulmonary firm, as the two companies said they will explore “commercial synergies.”
Medtech Insight - April 20, 2026

ACNU’s Simultaneous OTC/Rx Access Requirement Criticized By CHPA, PhRMA, Supported By AAM
Groups noted simultaneous OTC/Rx availability required for OTC switches approved through “additional conditions for nonprescription use” pathway in comments submitted in advance of meeting Duke-Margolis Institute for Health Policy conducts for FDA on April 23.
HBW Insight - April 21, 2026

ANI Bolsters US Generics Offering With Two Launches
Following two recent generic approvals from the US Food and Drug Administration, ANI Pharmaceuticals continues to widen its generic portfolio with the addition of carbamazepine and isosorbide mononitrate.
Generics Bulletin - April 20, 2026

Lupin Follows Sandoz, Sun In Antitrust Suit Settlement; $30m For Humana
Lupin has followed Sandoz and Sun Pharma in settling antitrust litigation on alleged price-fixing. This $30m settlement with US insurance giant Humana denies all allegations and does not imply admission of liability, but could more settlements be in the offing?
Generics Bulletin - April 20, 2026

Reddy’s Brazil Setback Signals Tougher Semaglutide Path
Brazil’s regulator has rejected three GLP-1 filings, including Dr Reddy’s semaglutide bid, despite fast-track measures to boost supply. The setback comes as patent expiries, surging demand and new investment intensify the race for Latin America’s biggest obesity market.
Generics Bulletin - April 20, 2026

Data Governance: Do You Have What It Takes to Realize the Promise of AI?
Genedata experts argue AI's promise in drug discovery depends less on algorithms than on data quality, and most organizations' data governance is not yet fit for purpose.
In Vivo - April 20, 2026

Another One Bites The Dust: Iterum Shuts Shop As Antibiotic Woes Drag On
High post-approval costs, weak returns and low initial uptake continue to weigh on antibiotics.
In Vivo - April 20, 2026

The Chemist Who Wants To Reprogram Drug Discovery
Lee Cronin wants to build the AWS of molecular discovery. His Glasgow-based startup Chemify is making the molecules to prove it.
In Vivo - April 20, 2026